XOMA Royalty Corporation successfully completed its tender offer to acquire all outstanding shares of Generation Bio Co. for $4.2913 per share in cash plus one contingent value right. Approximately 70% of Generation Bio's outstanding shares were validly tendered by the February 6, 2026 expiration date, satisfying the minimum tender condition. Following the acquisition, Generation Bio became a wholly owned subsidiary of XOMA Royalty and ceased trading on Nasdaq.

Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital hyperinsulinism. XOMA's stock fell 22.76% on the news.

XOMA Royalty Corporation announced its Board of Directors has authorized quarterly cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Series A holders will receive $0.53906 per share, while Series B depositary share holders will receive $0.52344 per depositary share. Dividends will be paid on or about January 15, 2026, to shareholders of record as of January 2, 2026.

XOMA Royalty Corporation announced an agreement to acquire Generation Bio for $4.2913 per share, with additional contingent value rights for stockholders. The acquisition is expected to close in February 2026 and includes potential milestone and royalty payments.

Mural Oncology has completed a scheme of arrangement with XOMA Royalty, where XOMA will acquire the entire issued share capital of Mural. The transaction became effective on December 5, 2025, with share trading cancellation and shareholder consideration distribution expected soon.

Mural Oncology has received High Court approval for a scheme of arrangement where XOMA Royalty will acquire the entire share capital of Mural. The acquisition is expected to become effective on December 5, 2025, with Mural shares to be delisted from Nasdaq on December 4, 2025.

Mural Oncology announced the final details of its acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with a total cash consideration of $2.035 per share. The acquisition is expected to close in early December 2025, subject to Irish High Court sanction.

Mural Oncology shareholders voted to approve an acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with over 99% of votes cast in favor. The transaction values Mural at approximately $36.2 million and is expected to close in Q4 2025.

XOMA Royalty and LAVA Therapeutics amended their share purchase agreement, reducing the initial cash amount per share to $1.04 and introducing a contingent value right (CVR). The tender offer has been extended to November 12, 2025, with the acquisition expected to close in Q4 2025.

XOMA Royalty has extended its tender offer to purchase all outstanding shares of LAVA Therapeutics until October 17, 2025, with a cash payment and a contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.

XOMA Royalty Corporation has extended its tender offer to purchase LAVA Therapeutics shares until October 17, 2025, with a cash payment and contingent value right per share. The proposed acquisition is expected to close in Q4 2025, subject to customary closing conditions.

Mural Oncology is being acquired by XRA 5 Corp., a subsidiary of XOMA Royalty, through a scheme of arrangement. The definitive proxy statement has been mailed to shareholders, with meetings scheduled for October 24, 2025 to vote on the acquisition.